Gravell, R.; Frood, R.; Littlejohns, A.; Casanova, N.; Goody, R.; Podesta, C.; Albazaz, R.; Scarsbrook, A.
Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Curr. Oncol. 2024, 31, 6384-6394.
https://doi.org/10.3390/curroncol31100474
AMA Style
Gravell R, Frood R, Littlejohns A, Casanova N, Goody R, Podesta C, Albazaz R, Scarsbrook A.
Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology. 2024; 31(10):6384-6394.
https://doi.org/10.3390/curroncol31100474
Chicago/Turabian Style
Gravell, Rachel, Russell Frood, Anna Littlejohns, Nathalie Casanova, Rebecca Goody, Christine Podesta, Raneem Albazaz, and Andrew Scarsbrook.
2024. "Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment" Current Oncology 31, no. 10: 6384-6394.
https://doi.org/10.3390/curroncol31100474
APA Style
Gravell, R., Frood, R., Littlejohns, A., Casanova, N., Goody, R., Podesta, C., Albazaz, R., & Scarsbrook, A.
(2024). Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology, 31(10), 6384-6394.
https://doi.org/10.3390/curroncol31100474
